Moderna inks fill-finish pact with Spain's Rovi for 'hundreds of millions' of COVID-19 shot doses

Moderna is on a steady march to market with its mRNA-based COVID-19 vaccine, and the company is snapping up manufacturing capacity along the way. After inking one fill-finish deal with major CDMO Catalent last month, Moderna has now put its name to a second pact.